Back to Rankings

NUTX

Nutex HealthA
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart

AI scenario view

RankAlpha Sentiment Codex
B+
Bull case
25%
Probability
Target price
$190.00
+52.0% vs current
Most likely
B
Base case
50%
Probability
Target price
$145.00
+16.0% vs current
B-
Bear case
25%
Probability
Target price
$92.00
-26.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-29
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+63.4
Score

AI commentary

Primary filings are constructive, but this remains a low-coverage monitoring setup rather than a high-conviction re-rate. The packet does not provide a trustworthy analyst revision wave or a clean post-print market-reaction readout, and the arbitration-driven model keeps forward visibility uneven. Social context was unavailable, so it did not influence the thesis.

RankAlpha Sentiment Codex - 2026-05-29
Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2026-04-30eventQ1 2026 results reinforced cash generation and the arbitration thesisHigh impact

Nutex reported Q1 2026 revenue of $216.5 million, diluted EPS of $6.52, operating cash flow of $75.5 million, and $207.3 million of cash and equivalents; management said the quarter was helped by favorable developments in the arbitration process, which improved revenue and cash collections [#8-K-2026-04-30] [#10-Q-2026-04-30].

2026-06-30catalystQ1 repurchases can still support per-share metricsMedium impact

The company repurchased and retired 200,444 shares in Q1 2026 for $31.7 million, so continued buybacks could support EPS and per-share value if operating cash flow remains strong [#10-Q-2026-04-30].

2026-12-31catalystHospital pipeline still gives the model long-run optionalityHigh impact

As of December 31, 2025, Nutex still had 17 under-construction hospitals, including three that had not opened yet and four with abandoned development plans, which keeps the growth pipeline alive but also highlights execution risk [#10-K-2026-03-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-05-29 • Updated nightlySource: Internal modelMethodology